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1. Introduction
An impure substance may be defined as any material that affects the purity of the material of interest, viz., an  
active pharmaceutical ingredient (API) or drug substance. Impurity control in pharmaceutical products is a primary goal of 
drug development. Stringent international regulatory requirements have been in place for several years as outlined in the 
International Conference on Harmonization (ICH) Guidelines Q3A(R), Q3B(R) and Q3C [1–3]. The purity of a drug product 
is in turn determined on the basis of the percentage of the labeled amount of API found in it by a suitable analytical method. 
Later discussion will also reveal that a drug product can have impurities that need to be monitored even though they do not  
affect the labeled content.  Degradation product impurities in drug products are of primary concern while process-related 
impurities and degradation products are both necessary to control in APIs. Many potential impurities result from the API 
manufacturing process including starting materials, isomers, intermediates, reagents, solvents, catalysts and reaction by-
products. These potential impurities should be investigated to determine process control mechanisms for their removal and 
the need for specification controls at appropriate points in the process. Several descriptions have appeared in the literature  
for impurity investigations and method development to support them [4,5] . As for impurity profiling, it is the common name 
of analytical activities with the aim of detecting, identifying or elucidating the structure and quantitatively determining  
organic and inorganic impurities as well as residual solvents in bulk drugs and pharmaceutical formulations [5] . 
The  different  pharmacopoeias,  such as  the  British Pharmacopoeia  (BP)  and  the  United  States  Pharmacopoeia 
(USP)  are  slowly incorporating  limits  to  allowable  levels  of  impurities  present  in  the  API’s  or  formulations.  Various  
regulatory authorities like ICH, USFDA, Canadian Drug and Health Agency are emphasizing on the purity requirements 
and the identification of impurities in Active Pharmaceutical Ingredient’s (API’s). Qualification of the impurities is the  
process of acquiring and evaluating data that establishes biological safety of an individual impurity thus, revealing the need  
and scope of impurity profiling of drugs in pharmaceutical research. A number of recent articles  17-18 have described a 
designed approach and guidance for isolating and identifying process-related impurities and degradation products using 
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Chromatographic and Spectroscopic techniques, either alone or in combination with other techniques. Analysis has gone 
beyond traditional chromatographic techniques, such as HPLC and GC, in order to resolve potential impurities through  
efforts  that  embrace  diverse  chemical  environments.  This  concept  is  known as  ‘orthogonality’.  One  such  employable  
orthogonal technique is Supercritical Fluid Chromatography (SFC). SFC is considered a normal phase technique because it  
utilizes the relatively nonpolar, liquid carbon dioxide as the bulk of the mobile phase and due to higher diffusivity of the  
mobile phase yields greater efficiency.
2. Impurity profile and drug safety
The safety of drug therapy is closely related to the quality of drugs. The requirements with respect to the active 
ingredient content of bulk-drug materials in the various pharmacopoeias are usually in the range 98–99% [6-8]. The aim is to 
minimize the adverse effects of drug materials and the preparations made thereof. After establishing the pharmacological-
toxicological profile of a drug substance, pharmacologists, clinicians and drug-registration authorities consider its beneficial  
and adverse effects to the human organism and, on the basis
of the benefit/risk ratio thus obtained, make the decision with respect to the possibility of introducing it into therapy.
3. Sources of impurities in drug products
In general, the various types of impurities that may be present in pharmaceutical substances can come from the  
following sources:
3.1. Synthesis-related impurities
Impurities in a drug substance or a new chemical entity (NCE) originate mainly during the synthetic process from 
raw materials, solvents, intermediates, and by-products. The raw materials are generally manufactured to much lower purity 
requirements than a drug substance. Hence, it is easy to understand why they can contain a number of components that can 
in turn affect the purity of the drug substance. Similarly, solvents used in the synthesis are likely to contain a number of  
impurities  that  may range from trace  levels  to  significant  amounts  that  can  react  with various chemicals  used  in  the 
synthesis to produce other impurities. Intermediates are also not generally held to the purity level of the drug substance—
hence the remarks made for the raw materials apply. It is not reasonably possible to theorize all by-products; as a result, any  
such  products  that  may be  produced  in  the  synthesis  would  be  hard  to  monitor.  The  “pot  reactions,”  i.e.,  when  the 
intermediates are not isolated,  are convenient,  economical,  and timesaving;  however,  they raise havoc in terms of  the 
generation of impurities because a number of reactions can occur simultaneously. Incidentally, this problem of numerous 
reactions occurring simultaneously can be also encountered in single reactions where intermediate is isolated.
3. 2. Formulation-related impurities
These impurities may be :-
3.2.1 Method Related 
eg- diclofenac sodium ampoule – indoline-2 one(impurity) is formed in the production of parenteral dosage form if it is 
terminally sterilized by autoclave because concentration of the impurity in the ampoule exceeds the limit of the raw material 
in the BP.
3.2.2 Environmental related
Exposures to adverse temperatures.  Eg -  vitamin products in liquid formulations Expose to light (UV light). Ergometrine 
injections shows complete degradation when kept 42 hrs in direct sunlight.
Humidity e.g., Aspirin, Ranitidine & other hygroscopic products.
3.2.3  Dosage  form  related:  In  general  ,  liquid  dosage  form  are  very  much  susceptible  to  both  degradation  and 
microbiological contamination. In this regard , water content , pH of solution, mutual interaction of ingredient and the 
primary container are critical factor.
3.3.  Degradation-related  impurities:  A number  of  impurities  can  be  produced  because  of  API  degradation  or  other 
interactions on storage,  Eg :  Nicotinamide presence in a  formulation containing 4 vitamins (nicotinamide, pyridoxine, 
riboflavin and thiamine) causes degradation of thiamine to a substandard level within a 1-year shelf life of Vitamin B-
complex injections. Therefore, it is very important to conduct stability studies to predict, evaluate, and ensure drug product 
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safety[9]. Stability studies include evaluation of stability of API, preformulation studies to evaluate compatibility of API  
with the excipients to determine its stability in the formulation matrix, accelerated stability evaluations of the test or final  
drug product,  stability evaluation via kinetic studies and projection of expiration date,  routine stability studies of drug 
products in marketed, sample or dispensed package under various conditions of temperature light, and humidity.
The  stability  studies  under  various  exaggerated  conditions  of  temperature,  humidity,  and  light  can  help  us  
determine what potential impurities can be produced by degradation reactions[10].
3.3.1 Kinetic studies: Most of the degradation reactions of pharmaceuticals occur at finite rates and are chemical in nature. 
These reactions are affected by conditions such as solvent,  concentration of reactants,  temperature, pH of the medium, 
radiation energy, and the presence of catalysts. The order of the reaction is described by the manner in which the reaction 
rate depends on the concentration of reactant. The degradation of most pharmaceuticals can be classified as zero order, first 
order, or pseudo-first order, even though they may degrade by complicated mechanisms, and the true expression may be of  
higher order or be complex and noninteger.
4. Classification of impurities
For each API there should be an impurity profile describing the identified and unidentified impurities present in a 
typical batch. The impurity profile is normally dependent upon the process or origin of the API1. 
According to ICH guidelines,1 impurities associated with API’s are classified into the following categories:
a. Organic impurities (Process and Drug-related)
b. Inorganic impurities
c. Residual solvents
a.  Organic  Impurities:  Organic  impurities  may  arise  during  the  manufacturing  process  and/or  storage  of  the  drug 
substance.  They  may  be  identified  or  unidentified,  volatile  or  non-volatile,  and  these  include  the  starting  material, 
intermediates, degradation products, by-products and reagents, ligands and catalyst used at different stages of synthesis of  
API and drug products. These are described as follows:-
Starting materials or intermediates: These are the most common impurities found in every API unless a proper care is  
taken  in  every step  involved  throughout  the  multi-step  synthesis.  Although the  end  products  are  always  washed with  
solvents, there are always chances of having the residual unreacted starting materials unless the manufacturers are very  
careful about the impurities. In paracetamol bulk, there is a limit test for p-aminophenol, which could be a starting material  
for some one manufacturer or be an intermediate for the other.
By-products: In synthetic organic chemistry, getting a single end product with 100% yield is very rare; there is always a  
chance of having by-products. By-products from the side reactions are among the most common process impurities in drugs 
11,  12.  By-products  can  be  formed  through  a  variety  of  side  reactions,  such  as  incomplete  reaction,  overreaction,  
isomerization, dimerization, rearrangement, unwanted reactions between starting materials or intermediates with chemical 
reagents or catalysts 13.
Degradation products:  Impurities can also be formed by degradation of the end product during manufacturing of bulk 
drugs. However, degradation products resulting from storage or formulation to different dosage forms or aging are also 
common impurities  in  the  medicines.  The  degradation  of  penicillins  and  cephalosporins  is  a  well-known example  of 
degradation products. The presence of a ß-lactam ring as well as that of an α-amino group in the C6/C7 side chain plays a 
critical role in their degradation 14, 15.
Reagents, ligands and catalysts:  These chemicals are less commonly found in API’s; however, in some cases they may 
pose a problem as impurities. It has also been found that the presence of certain chemicals such as triethylamine has a  
degradative effect on the product. Ampicillin trihydrate samples having triethylamine content of 2000 ppm to 4000 ppm 
(determined by visual color method developed by Gist- Brocades, Delft, Holland) were found to be stable under accelerated 
stability testing. However, the product showed appreciable degradation when triethylamine content became 7000 ppm 15.
Chemical reagents, ligands and catalysts used in the synthesis of a drug substance can be carried over to the final products 
as trace level impurities. For e.g. carbonic acid chloromethyl tetrahydro-pyran-4-yl ester (CCMTHP), which is used as an  
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alkylating agent in the synthesis of a β-lactam drug substance, was observed in the final product as an impurity. Many  
chemical reactions are promoted by metal based catalysts. For instance, a Ziegler-Natta catalyst contains titanium, Grubb’s  
catalyst contains ruthenium and Adam’s catalyst contains platinum. In some cases, reagents or catalysts may react with 
intermediates  or  final  products  to  form  byproducts.  For  e.g.,  Pyridine,  a  catalyst  used  in  the  course  of  synthesis  of  
mazipredone, reacts with an intermediate to form a pyridinium impurity13.
b. Inorganic Impurities: 
Inorganic impurities  can result  from the manufacturing process.  They are normally known and identified and 
include:
• Reagents, ligands and catalysts
• Heavy Metals or other residual metals
• Inorganic salts
• Other materials (filter aids, charcoal)
Reagents, ligands and catalysts: The chances of having these impurities are rare however, in some processes; these could 
create a problem unless the manufacturers take proper care during production.
Heavy metals: The main sources of heavy metals are the reactors (if stainless steel reactors are used), where acidification or 
acid hydrolysis takes place and water used in the processes. These impurities of heavy metals can easily be avoided using 
demineralized water and glass-lined reactors.
Filter  aids,  Charcoal:  The  filters  or  filtering  aids  such  as  centrifuge  bags  are  routinely  used  in  the  bulk  drugs  
manufacturing plants, and in many cases, activated carbon is also used. The regular monitoring of fibers and black particles 
in the bulk drugs is essential to avoid these contaminations.
c. Residual solvents: Residual solvents are organic volatile chemicals that are used or produced in the manufacture of drug 
substances or excipients, or in the preparation of drug products. The residual solvents 3 are classified as follows:
Class 1 solvents: Solvents to be avoided in pharmaceutical products Known human carcinogens, strongly suspected human 
carcinogens and environmental hazards. Example was shown in Table 1
Class 2 solvents: Solvents to be limited in pharmaceutical products:  Non-genotoxic animal carcinogens or possible 
causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity. solvents suspected of other significant  
but reversible toxicities. Example was shown in Table 2
Class 3 solvents: Solvents with low toxic potential: Solvents with low toxic potential to man; no health -based exposure 
limit is needed.
These solvents are less toxic in acute or short term studies and negative in genotoxic studies. The amount of these residual  
solvents of 50mg or less would be acceptable. Examples : Acetic acid, Acetone, Anisole, 1-Butanol, 2-Butanol etc.
Class 4 solvents: Solvents for which No adequate toxicological data was found: The solvents may be of interesting to 
manufacturers of excipients, drug substances or drug products. But there was no adequate toxicological data on which to 
base  a  Permitted  Daily  Exposure  was  found.  Examples:  1,1-Diethoxy propane,1,1-Dimethoxy propane,2,2-Dimethoxy 
propane, Isooctane etc.
Table 1: Solvents to be avoided in pharmaceutical products
Solvent Concentration limit (ppm) concern
Benzene 2 Carcinogen
CCl4 4 Toxic and environmental hazard
1,2-Dichloroethane 5 Toxic
1,1-Dichloroethane 8 Toxic
1,1,1-Trichloroethane 1500 Environmental hazard
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Table 2: Solvents to be limited in pharmaceutical products
Solvent Permitted Daily Exposure a (mg/day) Concentration limit (ppm)
Acetonitrile 4.1 410
Chlorobenzene 3.6 360
Chloroform 0.6 60
Cyclohexane 38.8 3880
1,2-Dichloroethane 18.7 1870
4. Others
Enantiomeric impurities:  There are many drugs in which only single enantiomer is active.  In such cases the inactive 
enantiomer is considered as an impurity, e. g. In pilocarpine only Dextro form is active, here levo form is considered as an 
impurity.
Identification and qualification thresholds of  impurities  & Limits:  The International  Conference on Harmonisation 
addresses questions relating to impurities as follows :
Q1A (R) stability testing of new drug substances and products
Q3A (R) impurities in drug substances
Q3B (R) impurities in drug products
Q3C impurities: residual solvents
Q6A specifications:  test  procedures and acceptance criteria  for  new drug substances and new drug products;  chemical 
substances.
Limits for impurities: According to ICH guidelines on impurities in new drug products, identification of impurities below 
0.1% level, is not considered to be necessary, unless potential impurities are expected to be unusually potent or toxic.  
According to ICH, the maximum daily dose qualification threshold to be considered is as follows as shown in Table 3.
As can be seen from the data in Table 4, ICH treats the degradation products slightly differently than impurities 
even though for all intents and purposes the degradation products are impurities.
Table 3: Drug substance impurities thresholds
Maximum daily dose Reporting threshold Identification threshold Qualification threshold
≤ 2g/day 0.05% 0.10% or 1.0 mg/day
intake (whichever is less)
0.15% or 1.0 mg/day
intake(whichever is less)
≥ 2g/day 0.03% 0.05% 0.05%
Table 4:Thresholds for Reporting of Degradation Products in New Medicinal Products
Maximum Daily Dose Threshold
<1g 0.1%
> 1 g 0.05%
Selective analytical methodologies: A variety of methods are available for monitoring impurities. The primary criterion is  
the  ability  to  differentiate  between  the  compounds  of  interest.  This  requirement  reduces  the  availability  of  methods 
primarily to spectroscopic and separation methods or a combination thereof.
Spectroscopic methods: The following spectroscopic methods can be used:
▪ Ultraviolet (UV)
▪ Infrared (IR)
▪ Nuclear magnetic resonance (NMR)
▪ Mass spectrometry (MS)
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UV at a single wavelength provides minimal selectivity of analysis; however, with the availability of diode array 
detectors (DAD), it is now possible to get sufficient simultaneous information at various wavelengths to ensure greater  
selectivity.
Infrared spectrophotometry:  Infrared spectrophotometry provides specific information on some functional groups that 
may allow quantification and selectivity. However, low-level detectability is frequently a problem that may require more  
involved approaches to circumvent the problem.
Nuclear magnetic resonance spectroscopy:  Nuclear magnetic resonance spectroscopy provides fairly detailed structural 
information on a molecule and is a very useful method for characterization of impurities; however, it has limited use as a  
quantitative method because of cost and time considerations.
Mass spectrometry:  Mass spectrometry provides excellent  structural  information,  and,  based on the resolution of  the 
instrument,  it  may provide  an  effective  tool  for  differentiating molecules  with  small  differences  in  molecular  weight. 
However, it has limited use as a quantitative technique because of cost and time considerations.
In summary, IR, NMR, and MS are excellent techniques for characterization of impurities that have been isolated 
by any of the techniques discussed above. UV has been found to be especially useful for analyzing most samples with high-
pressure liquid chromatography. This combination is commonly used in pharmaceutical analysis.
Separation methods
The following separation methods can be used:
▪ Thin-layer chromatography (TLC)
▪ Gas chromatography (GC)
▪ High-pressure liquid chromatography (HPLC)
▪ Capillary electrophoresis (CE)
▪ Supercritical fluid chromatography (SFC)
Except  for  CE,  all  these  techniques  are  chromatographic  methods.  CE  is  an  electrophoretic  method  that  is 
frequently  lumped  with  the  chromatographic  methods  because  it  shares  many  of  the  common  requirements  of 
chromatography. However, it is not strictly a two-phase separation system — a primary requirement in chromatography. 
Hyphenated methods such as GC–MS, LC–MS, GC–LC–MS, LC–MS–MS, etc. are all discussed later in this chapter.
A broad range of compounds can be resolved using  TLC by utilizing a variety of different plates and mobile 
phases. The primary difficulties related to this method are limited resolution, detection, and ease of quantification. The 
greatest advantages are the ease of use and low cost.
Gas chromatography is a very useful technique for quantification. It can provide the desired resolution, selectivity, and 
ease of quantification. However, the primary limitation is that the sample must be volatile or has to be made volatile by  
derivatization. This technique is very useful for organic volatile impurities.
High-pressure  liquid  chromatography is  frequently casually referred  to  as  high-performance liquid  chromatography 
today. Both of these terms can be abbreviated as HPLC, and they are used interchangeably by chromatographers. This is a 
useful technique with applications that have been significantly extended for the pharmaceutical chemist by the use of a  
variety of detectors such as fluorescence, electrometric, MS, etc.
Capillary electrophoresis is a useful technique when very low quantities of samples are available and high resolution is  
required. The primary difficulty is assuring reproducibility of the injected samples.
Supercritical fluid chromatography offers some of the advantages of GC in terms of detection and HPLC in terms of 
separations, in that volatility of the sample is not of paramount importance. This technique is still evolving, and its greatest  
application has been found in the extraction of samples.
Hyphenated methods
The following hyphenated methods can be used effectively to monitor impurities :
▪ GC–MS
▪ LC–MS
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▪ LC–DAD–MS
▪ LC–NMR
▪ LC–DAD–NMR–MS
▪ LC–MS–MS
Isolation  methods:  Mostly  the  chromatographic  techniques  are  used  for  isolation  of  impurities  along  with  non-
chromatographic techniques are also rarely used.
It is often necessary to isolate impurities because the instrumental methods mentioned above are not available or  
further confirmation is needed. For example, when hyphenated methods such as LC–MS are not suitable or do not provide  
unambiguous  characterization,  it  may  be  necessary  to  isolate  impurities  for  further  confirmation  of  structure  or  for  
conducting toxicity studies.
The following methods have been used for isolation of impurities:
▪ Solid-phase extraction ▪ Column chromatography
▪ Flash chromatography ▪ Supercritical fluid chromatography
▪ Thin-layer chromatography ▪ Capillary electrophoresis
▪ Gas chromatography ▪ Supercritical fluid extraction
▪ High-pressure liquid chromatography  ▪ Accelerated solvent extraction
▪ Liquid–liquid extraction
Isolation  should  be  initiated  based  on  simple  extraction  or  partition  methods.  It  may be  possible  to  extract 
impurities selectively on the basis of acidity, basicity, or neutrality. The
extraction process usually involves liquid–liquid extraction, where one phase is an aqueous solution and the other is an 
organic phase that is nonpolar.
A case study:  A case study is presented below relating to monitoring impurities  in terbutaline sulfate (it  is  sold as  a  
racemate).
HPLC methods: The first step in this process was to review all potential sources of impurities in terbutaline.
Synthesis: starting materials, solvents used, intermediates, theorize potential by-products.
Formulation: solvents used, potential interaction products, any potential degradation products.
Stability: potential  degradation  products  or  reaction  products  that  may  be  produced  because  of  thermal,  hydrolytic, 
oxidation, or photochemical reactions.
A careful assessment revealed that there could be 13 potential impurities in terbutaline (for chemical names, see  
legends in Figs. 1 and 2) that must be resolved. HPLC was clearly indicated as the preferred methodology of choice, based  
on physicochemical properties of terbutaline[10].
Achiral impurities: All of the potential impurities were classified into four groups to assist the method development:
▪ Dihydroxyphenyl compounds with t-butylamino side chain
▪ Cyclized dihydroxyphenyl compounds with basic N in the ring
▪ Dibenzyloxyphenyl compounds with no t-butylamino side chain
▪ Dihydroxyphenyl compounds with no t-butylamino side chain
Two HPLC methods were developed to resolve all achiral impurities with the same C-8 column with 3-μm particle size [10].
System 1 (suitable for degradation products and less likely synthetic impurities): 0.005 mol 1-octanesulfonic acid  
in water:tetrahydrofuran:methanol (75:11:14).
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System 2 (suitable for dibenzyloxyphenyl compounds; starting material and intermediates): water:tetrahydrofuran: 
acetonitrile:acetic acid:triethylamine (500:465:35:5:2).
In summary, System 2 was designed primarily for quality control of API. Since no impurities were found in the API 
with System 2, the quality of drug product for QC and stability studies can be monitored using System 1 only.
Chiral impurities
The L-isomer of terbutaline is 3000 times more potent as a relaxant of tracheal smooth muscle than the D-isomer [19].
1. The isomers can be resolved on AGP column with 0.003 M tetrapropyl–ammonium bromide solution adjusted to pH 7.0.
2. Capillary electrophoresis can be used to resolve enantiomers with a background electrolyte that contains β-cyclodextrin  
or heptakis (2,6-di-O-methyl)-β-cyclodextrin.
Fig. 1. Resolution of potential degradation products
1=3,5-dihydroxyacetophenone,2=3,5  dihydroxybenzaldehyde,  3=2-t-butyl-4,6,8-trihodroxy-tetrahydroisoquinoline, 
4=terbutaline, 5=3,5-dihydroxy-ù-t-butylaminoacetophenone, 6=3,5-dihydroxybenzoic acid, ethyl ester. 
Fig. 2. Resolution of potential dibenzyloxyphenyl impurities
1=terbutaline,  2=solvent,  3=solvent,  4=α-[(t-butylamino)methyl]-3,5-dibenzyloxybenzyl  alcohol,  5=α-methyl-3,5-
dibenzyloxybenzyl  alcohol,  6=3,5-dibenzyloxyacetophenone,  7=α-[(benzyl-t-butylamino)methyl]-3,5-dibenzyloxybenzyl 
alcohol,  8=3,5-dibenzyloxy-2,6-dibromoacetophenone,  9=3,5-dibenzyloxy-1′-  bromoacetophenone,  10=3,5-dibenzyloxy-
2,6,α-tribromacetophenone, 11= 1′-benzyl-t-butylamino-3,5-dibenzyloxyacetophenone.
5. Conclusions
To assure quality of drug substances and drug products, it is important to give a careful consideration as to what  
constitutes impurities for a given case and proceed carefully to design a program to achieve the desired results. It is believed 
that the discussion included herein would be helpful in developing such a program.
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